Another world class retinal specialist is joining OHR. This guy is just the right guy to implement Phase III and see to Squalamine FDA approval:
"Dr. Ingerman's previous roles included serving as Vice President of Ophthalmology at Regeneron Pharmaceuticals, where he was responsible for the Eylea(R) development program, which was conducted in collaboration with Bayer Healthcare. "
Well, OCT and lesion size is one thing. While I agree that it matters, what matters a million times more is the fact that people SEE BETTER. And by the way: That is the only thing that FDA cares about for giving the go ahead for Squalamine.
We simply don't know.
There is nothing publicly available that gives us a clue.
Not good. We need some positive press releases from the company to tell us what is going on.
Trial results are due this month I believe. That will move the stock big time. But it can go either way.
If longs are lucky, we will see 20 again soon.
But 5 or less is also possible.